Aclid is a biotechnology security and compliance automation platform that provides real-time screening of gene synthesis orders and automatic verification of customer licenses and biosafety guidelines. This technology reduces the risk of misuse and streamlines compliance processes, enabling biotech manufacturers to minimize order cancellations and delays.
Funding
$3.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Biotech manufacturers face increasing pressure to comply with biosecurity regulations and prevent the misuse of gene synthesis technologies. Manual screening of gene synthesis orders and verification of customer credentials are time-consuming, error-prone, and can lead to order cancellations and delays.
Solution
Aclid offers a biotechnology security and compliance automation platform that streamlines the gene synthesis ordering process. The platform provides real-time screening of gene synthesis orders against a comprehensive threat database, delivering risk assessments in seconds. Aclid also automates the verification of customer licenses, registrations, biosafety guidelines, and legitimate use, reducing the need for manual follow-up and minimizing false alarms. By automating these processes, Aclid helps biotech manufacturers reduce risk, increase sales, and focus on growing their business.
Target Audience
Aclid's primary customers are biotech manufacturers and government organizations involved in gene synthesis and related biotechnologies.
Features
- Real-time screening of gene synthesis orders for potential biosecurity threats
- Automated verification of customer licenses, registrations, and biosafety compliance
- Comprehensive risk assessments and threat profiles delivered in seconds
- Streamlined compliance process with automated customer follow-up
- Up-to-date database of regulations, guidelines, and research